Cosentyx vs Dupixent
Side-by-side cost comparison based on Medicare Part D data
Cosentyx
Secukinumab
Manufactured by Novartis
Dupixent
Dupilumab
Manufactured by Regeneron/Sanofi
Dupixent costs 22% less per claim than Cosentyx ($2,819.00 vs $3,616.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Cosentyx | Dupixent |
|---|---|---|
| Avg Cost Per Claim | $3,616.00 | $2,819.00 |
| Total Medicare Spending | $3.1B | $4.4B |
| Total Beneficiaries | 120,000 | 245,000 |
| Total Claims | 864,000 | 1,560,000 |
| Annual Cost/Patient | $26,033.00 | $17,951.00 |
| Year-over-Year Change | +8.9% | +35.2% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Mar 28, 2031 |
| Manufacturer | Novartis | Regeneron/Sanofi |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Secukinumab | Dupilumab |
Cosentyx vs Dupixent: What the Data Shows
Cosentyx (Secukinumab) and Dupixent (Dupilumab) are both used to treat autoimmune diseases. Based on Medicare Part D data, Dupixent costs $2,819.00 per claim, which is 22% less than Cosentyx at $3,616.00 per claim.
Medicare spent $3.1B on Cosentyx and $4.4B on Dupixent. In terms of patient reach, Dupixent serves more beneficiaries (245,000 vs 120,000).
Year-over-year spending changed +8.9% for Cosentyx and +35.2% for Dupixent. Dupixent saw significant spending growth, suggesting increased utilization or price increases.
Cosentyx has a generic available, while Dupixent remains brand-only until its patent expires Mar 28, 2031.
Frequently Asked Questions
Dupixent is cheaper at $2,819.00 per claim, compared to $3,616.00 for Cosentyx. That makes Dupixent about 22% less expensive per claim based on Medicare Part D data.
Yes, both Cosentyx and Dupixent are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Cosentyx has a generic version (Secukinumab) available, which is typically much cheaper. Dupixent is currently brand-only, with patent expiring Mar 28, 2031.
Medicare Part D spent $3.1B on Cosentyx covering 120,000 beneficiaries, and $4.4B on Dupixent covering 245,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.